Uncertainties Surround Optimal Dosing of Cytarabine in AML
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
Incorporating 2 standardized documents into the process for supportive care measures improved outcomes for patients receiving HD-MTX.
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.
Retrospective analysis demonstrates the value in distinguishing between these conditions to salvage chemotherapy and/or targeted therapy dose in patients with cancer.
Although other flow cytometry–based prognostic scores have been proposed in the setting of MDS, their complexity has limited their clinical use.
An analysis of data from the NIH-AARP Diet and Health Study evaluated the association between consumption of various foods and the development of MPN.
This approach requires a team-coordinated effort by investigators, patients, and caregivers, as well as genomic and cytogenetic laboratories.
Peripheral T-cell lymphoma is characterized by extensive epigenetic dysregulation.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.